InMed Pharmaceuticals (US: INM)

Currency in -

Last close As at 02/06/2023

-0.37

−0.02 (−5.13%)

Market capitalisation

USD6m

Edison Investment Research is terminating coverage on InMed Pharmaceuticals. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 2.6 (49.4) (82.2)
Relative (8.3) (53.6) (81.7)
52 week high/low US$2.4/US$0.4

Financials

Edison Investment Research is terminating coverage on InMed Pharmaceuticals. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Y/E Jun Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (c) P/E (x) P/CF (x)
2020A 0.0 (9.0) (9.0) (172.80) N/A N/A
2021A 0.0 (9.8) (10.3) (153.02) N/A N/A
2022E 1.8 (14.6) (14.8) (97.62) N/A N/A
2023E 10.2 (13.2) (13.8) (63.67) N/A N/A

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free